Savvipharm Inc

Tactical Therapeutics Inc.

Other

Rashida A Karmali

Lloyd Provenzano

Felix Wehrmann

This invention provides compositions and methods for treatment of mild, moderate and severe stages of SARS-CoV-2 infection, particularly COVID-19 disease caused by wild type and mutant strains of SARS-CoV-2 using 5-amino-1-(4-(4-chlorobenzyl)-1, 2, 3-triazole-4-carboxamide orotate. Carboxyamidotriazole orotate (CTO) alone or in combination with other therapeutics in standard of clinical care are useful for directing antiviral effects and host-directed antiviral effects against wild type and mutant strains of SARS-CoV-2 throughout the viral life cycle.

Methods and compositions for treating SARS-CoV-2 infection using carboxyamidotriazole orotate

This invention provides methods, pharmacodynamics biomarker signatures for multiple signaling pathways in a cell sample such as anagen hair, in response to carboxyamidotriazole orotate (CTO) from a subject. CTO has demonstrated response in several cancers having different genomic mutations in clinical studies. This invention provides a diagnostic and prognostic assay for monitoring response to CTO ranging from &#x2212;100 fold to +25 fold differential expression in several transcriptional signatures associated with tumor inhibition including EGFR, MEK, HDAC, RAS, GFS, WNT, HSP90 or non-voltage dependent calcium signaling, while inducing tumor suppressors signatures such as P53 or EGR1 in the anagen hair assay.

Methods and molecular pharmacodynamic biomarkers for multiple signaling pathways in response to carboxyamidotriazole orotate

This invention provides methods and compositions useful for treating early and late stage metastatic cancer to prevent or treat acquired resistance due to gene amplification or mutation in response to chemotherapeutic and/or targeted drugs. In particular, the methods and compositions include carboxiamidotriazole orotate (CTO) alone or in combination with specific regimens of chemotherapeutic and/or targeted drugs designed to overcome the genomic resistance raised to prior therapy.

Compositions for treating cancers having acquired resitance to prior chemotherapeutic and targeted drugs using carboxyamidotriazole orotate

New polymorphs of 5-amino or substituted amino 1,2,3-triazole and substituted derivatives thereof, of orotates of the carboxyamidotriazoles, of formulations of the triazoles and orotic acid in the ratio of 1:1 to 1:4 (base:acid) and of safer processes of the preparation of the same are disclosed. The compounds are useful in the control and treatment of diseases including, but not limited to solid cancers, macular degeneration, retinopathy, chronic myeloid leukemia, AIDS and diseases which rely on aberrant signal transduction. The improved processes to prepare the orotate formulations use stable, efficient and safer starting azide intermediate materials in the synthesis of new polymorphs of carboxyamidotriazole.

Compositions and processes for preparing 5-amino or substituted amino 1,2,3-triazoles and triazoles orotate formulations

This invention relates to enhancing sensitivity of cytotoxic drugs by targeting their interfering mechanisms induced in the tumor microenvironment which lead to drug resistance, using combinatorial therapy with carboxyamidotriazole orotate. Specific doses of cytotoxic drugs are titrated with carboxyamidotriazole orotate to improve the sensitivity and anticancer activity of cytotoxic drugs.

Methods and compositions for enhancing sensitivity of cytotoxic drugs with timely combinatorial therapy with carboxyamidotriazole orotate

This invention is in the field of anthracycline family of drugs. More particularly, it concerns converting daunorubicin hydrochloride to an orotate salt and providing methods of improving the tolerability of daunorubicin in animals by reducing the adverse effects and toxicity in noncancerous tissues. Daunorubicin orotate provides a safer treatment for specific types of leukemias and neuroblastomas in adults and in pediatric patients.

Compositions and methods of improving the tolerability of daunorubicin when given as orotate salt

Method and composition of Carboxyamidotriazole orotate for treating age-related macular degeneration and other angiogenesis-dependent diseases.

Use of Carboxyamidotriazole (CAI) orotate in macular degeneration

This invention is related to orotic acid compounds of taxane cytotoxic agents and in particular to the conversion of the taxanes to their orotate esters. More particularly the pharmaceutical compositions of paclitaxel orotate and docetaxel orotate provide a strategy to minimize body weight loss during primary chemotherapy and improve patient outcomes and quality of life.

Pharmaceutical compositions containing paclitaxel orotate

Compositions and processes for preparing 5-amino or substituted amino 1,2,3-triazoles and triazole orotate formulations

This invention is in the field of chemical restructuring of pharmaceutical agents known to cause tissue toxicity as a side effect, by producing their orotate salts. More particularly, it concerns orotate salts of the anthracyclines, doxorubicin and daunorubicin, that are found to reduce levels of the pharmaceutical agent in noncancerous tissues. The orotate salts are equally efficacious in inhibiting the SCCAKI-1 kidney tumor in animals and the reduction in the heart tissue of doxorubicin compared with doxorubicin HCl suggests a reduction in toxicity induced by free radical generation by the anthracyclines.

Method of reducing cardiac levels of doxorubicin when given as orotate salt

The present invention relates generally to the method of increasing the oral bioavailability, reducing chemotherapy induced toxicity and side effects, and improving the effectiveness of pharmaceutical agents that are poorly absorbed from the gastrointestinal tract. Specifically, the invention relates to poorly absorbed pharmaceutical drugs and converting them to orotate salts. The orotate salts of the drugs can be dosed at lower doses to provide the efficacy benefits of a higher dose, while reducing the drugs' toxic effects at lower doses. Additionally, the orotate salts of pharmaceutical agents have better clearance and reduce the potential for drug-induced hepatic toxicity. Therefore, an especially useful formulation of the orotate salt of the pharmaceutical agent can provide rapid and consistent action using a lower dose while reducing drug interactions and side-effects.

Method of increasing drug oral bioavailability and compositions of less toxic orotate salts

Use of carboxiamidotriazole (CAI) orotate in macular degeneration

This invention is in the field of chemical restructuring of antimetabolite agents known to have poor oral bioavailability and to cause tissue toxicity as a side effect, by producing their orotate derivatives. More particularly, it concerns orotate derivatives of the methotrexate and trimetrexate, that are found to improve the oral bioavailability and clearance compared with their respective forms&#x2014;methotrexate and trimetrexate, currently in use. The present invention provides methotrexate orotate having the formula: 

Compositions and methods of reducing side effects and toxicity of methotrexate when given as orotate derivatives

This invention is in the field of chemical restructuring of pharmaceutical agents known to cause tissue toxicity as a side effect, by producing their orotate derivatives. More particularly, it concerns orotate derivatives of the anthracyclines, doxorubicin and daunorubicin, that are found to reduce levels of the pharmaceutical agent in noncancerous tissues. There orotate derivatives are equally efficacious in inhibiting the SCCAKI-1 kidney tumor in animals and the reduction in the heart tissue of doxorubicin compared with doxorubicin HCl suggests a reduction in toxicity induced by free radical generation by the anthrracyclines.

Compositions and methods of reducing tissue levels of drugs when given as orotate derivatives

A specimen collecting, processing and analytical assembly, designed for testing small volumes of body fluids, substances and secretions, said assembly comprising a one piece barrel assembly with a volumetrically graduated capillary tube having an open end, and optionally coated internally with an anticoagulant, a stabilizer or a preservative. The barrel assembly includes a filter membrane fitted above the capillary end at the junction of the barrel assembly and the capillary tube, a support means at the barrel's second open end, and an analytical testing means disposed there between. The invention also provides a sealed vial containing an analytical testing reagent, the vial being substantially airtight and sealed with a pierceable material, a first tip cap for closing the open end of the capillary tube, a second cap to close sealably the second open end of the barrel container and a lancet to induce capillary skin punctures.

Growing community of inventors

Brooklyn, NY, United States of America

Rashida A Karmali